3,5-Dimethyl-4-pyron | 19083-61-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 英文名称: 3,5-Dimethyl-4-pyron
• 英文别名: 3,5-Dimethyl-4H-pyran-4-one；3,5-dimethylpyran-4-one
• CAS: 19083-61-5
• 化学式: C₇H₈O₂
• 分子量: 124.139
• InChiKey: TYNBCLRVUQVAEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,5-Dimethyl-4-pyron 在 四丁基硫酸氢铵 、 过氧化苯甲酰 sodium hydroxide 、 N-溴代丁二酰亚胺(NBS) 作用下， 以 四氯化碳 、 二氯甲烷 为溶剂， 反应 8.0h， 生成 3-<<(2'-Furyl)methoxy>methyl>-5-methyl-4H-pyran-4-one
  参考文献：
  名称：

  Intramolecular [4 + 3]-cycloadditions of photochemically generated oxyallyl zwitterions: a route to functionalized cyclooctanoid skeletons

  摘要：

  [4 + 3]-Cycloaddition of photochemically generated, 4-pyrone derived oxyallyl zwitterions and furans was examined as a potential approach to keto-bridged cyclooctenes. In one case, intermolecular cycloaddition proceeded to give adduct 3 with complete diastereoselectivity and in moderate yield, but the reaction was not general. Substrates 5a-i were then prepared in one to three steps from either 3-methyl-4H-pyran-4-ones or 3-hydroxy-2-methyl-4H-pyran-4-one, and their viability in intramolecular [4 + 3]-cycloadditions was examined. Substrates 5a-e, in which the tether was attached to the incipient zwitterion via a carbon, underwent cycloaddition to give [4 + 3]-cycloadducts 7 and 8 in varying yields, along with small amounts of cage compound 9. In contrast, 5f-i, in which the tether was attached to the incipient zwitterion via an oxygen, gave only solvent-trapping products 10. In one case (5e), isomeric pyran-2-ones 11e/12e were produced in addition to [4+3]-cycloadduct 8e and cage compound 9e. Moreover, it was found that 11e and 12e both underwent subsequent photochemical crossed [4 + 4]-cycloadditions to give lactone-bridged cyclooctadienes 13e and 14e. The structures of 11e/12e and their [4 + 4]-cycloadducts were confirmed by synthesis of each of the 2-pyrones via alternative routes.

  DOI：

  10.1021/jo00076a047

文献信息

• PROCESS FOR PRODUCING AROMATIC POLYCARBOXYLIC ACID
  申请人：Shibamoto Akihiro

  公开号：US20110071314A1

  公开（公告）日：2011-03-24

  A process for producing an aromatic polycarboxylic acid in which all alkyl groups are converted into carboxyl groups in a high yield by decreasing a residual amount of an intermediate product is provided. The process comprises oxygen-oxidizing an aromatic compound having a plurality of alkyl groups (e.g., durene) in the presence of a catalyst containing a cyclic imino unit having an N—OR group (wherein R represents a hydrogen atom or a protecting group for a hydroxyl group) and a transition metal co-catalyst (e.g., a cobalt compound, a manganese compound, and a zirconium compound) under heating in a lower-temperature zone and a higher-temperature zone to produce an aromatic polycarboxylic acid in which a plurality of alkyl groups are oxidized into carboxyl groups. In an initial stage of the reaction, the reaction may be conducted in a first lower-temperature zone (a reaction temperature of 60 to 120° C. and a second lower-temperature zone (an intermediate temperature zone) (a reaction temperature of 100 to 140° C.); and then, in a latter stage of the reaction, the reaction may be conducted in a higher-temperature zone (a reaction temperature of 110 to 150° C.).

  提供一种生产芳香族多羧酸的方法，其中所有烷基转化为羧基，产率高，通过减少中间产物的残留量实现。该方法包括在低温区和高温区加热的条件下，在催化剂的存在下，将具有多个烷基的芳香化合物（例如二甲苯）进行氧气氧化，其中催化剂包含具有N-OR基团（其中R代表氢原子或羟基的保护基团）和过渡金属共催化剂（例如钴化合物、锰化合物和锆化合物）的环状亚胺单元，以产生芳香族多羧酸，其中多个烷基被氧化为羧基。在反应的初始阶段，反应可以在第一低温区（反应温度为60至120°C）和第二低温区（中间温度区）（反应温度为100至140°C）进行；然后，在反应的后期阶段，反应可以在较高温度区（反应温度为110至150°C）进行。
• CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT
  申请人：Dasseux Jean-Louis Henri

  公开号：US20120035141A1

  公开（公告）日：2012-02-09

  The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

  本发明涉及新型环烷基-羟基化合物、包含羟基化合物的组合物以及用于治疗和预防各种疾病和病症的方法，例如但不限于衰老、阿尔茨海默病、癌症、心血管疾病、糖尿病肾病、糖尿病视网膜病变、葡萄糖代谢紊乱、脂质代谢紊乱、高血压、阳痿、炎症、胰腺炎、帕金森病、过氧化物酶体增殖物活化受体相关疾病、胆汁中磷脂消除、肥胖症、胆汁中氧化固醇消除、肾脏疾病、败血症、X综合症、血栓性疾病。本发明的化合物和方法还可用于调节C反应蛋白或增强患者的胆汁产生。在某些实施例中，本发明的化合物、组合物和方法可与其他治疗药物（如降胆固醇和降血糖药物）进行联合治疗。
• CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES
  申请人：Dasseux Jean-Louis Henri

  公开号：US20120172337A1

  公开（公告）日：2012-07-05

  The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

  本发明涉及新型环烷基-羟基化合物、包含羟基化合物的组合物，以及用于治疗和预防多种疾病和病况的方法，例如但不限于衰老、阿尔茨海默病、癌症、心血管疾病、糖尿病肾病、糖尿病视网膜病变、葡萄糖代谢紊乱、血脂异常、高血压、阳痿、炎症、胰腺炎、帕金森病、过氧化物酶体增殖物激活受体相关疾病、胆汁中脂质消除、肥胖症、胆汁中氧化固醇消除、肾病、败血症、X综合症、血栓性疾病。本发明的化合物和方法还可用于调节C反应蛋白或增强患者的胆汁产生。在某些实施例中，本发明的化合物、组合物和方法与其他治疗药物（如降胆固醇和降血糖药物）的联合治疗中有用。
• EP4 Receptor Agonist, Compositions and Methods Thereof
  申请人：Billot Xavier

  公开号：US20110237511A1

  公开（公告）日：2011-09-29

  This invention relates to potent selective agonists of the EP 4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.

  本发明涉及到前列腺素E2受体EP4亚型的有效选择性激动剂，其在治疗青光眼和其他与患者眼内压升高有关的疾病中的应用或制剂。本发明还涉及到将本发明的化合物用于介导成骨细胞和破骨细胞的骨建模和重塑过程。
• KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES
  申请人：DASSEUX Jean-Louis Henri

  公开号：US20120129930A1

  公开（公告）日：2012-05-24

  The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's disease, Syndrome X, peroxisome proliferator activated receptor related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

  本发明涉及新型酮类化合物、包含酮类化合物的组合物以及用于治疗和预防心血管疾病、血脂异常、蛋白异常和葡萄糖代谢紊乱的方法，包括给予含有酮类化合物的组合物。该发明的化合物、组合物和方法还可用于治疗和预防阿尔茨海默病、X综合征、过氧化物酶体增殖物激活受体相关疾病、败血症、血栓性疾病、肥胖症、胰腺炎、高血压、肾脏疾病、癌症、炎症和阳痿。在某些实施例中，该发明的化合物、组合物和方法可与其他治疗剂（如降胆固醇和降血糖药物）联合治疗。